Journals / Harran Üniversitesi Tıp Fakültesi Dergisi / 2020 / Cilt: 17 - Sayı: 3

Evaluation of Serum Cystatin C Levels And Its Relation with CEA, CA 19-9 in Patients with Gastric and Colorectal Cancer

Mide ve Kolorektal Kanserli Hastalarda Serum Sistatin C Düzeyi ve CEA, CA 19-9 ile İlişkisinin İncelenmesi

Pages
372–377
Publication Date
2020-12-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No significant relation between CEA, CA 19-9 and cystatin C was observed when participation in patient groups, age, sex and creatinine concentration were taken into consideration (p>0.05).Conclusion: Serum cystatin C concentrations of gastric and colorectal cancer patients may be affected due to the presence of cancer besides kidney function.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Cystatin C, a marker of kidney function, is thought to have inhibiting effects in tumor growth.
📊
Key Findings & Data:In the study comparing serum concentrations of cystatin C among gastric, colorectal cancer patients, controls and determination of its relation between serum CEA and CA 19-9 levels are aimed.Materials and Methods: Gastric cancer patients (n=35), colorectal cancer patients (n=35) and healthy subjects (n=40) without any known systemic disease were included in the study.
💡
Conclusion & Impact:No significant relation between CEA, CA 19-9 and cystatin C was observed when participation in patient groups, age, sex and creatinine concentration were taken into consideration (p>0.05).Conclusion: Serum cystatin C concentrations of gastric and colorectal cancer patients may be affected due to the presence of cancer besides kidney function.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:sistatin C · katepsin · mide kanseri

Abstract

Background: Cystatin C, a marker of kidney function, is thought to have inhibiting effects in tumor growth. In the study comparing serum concentrations of cystatin C among gastric, colorectal cancer patients, controls and determination of its relation between serum CEA and CA 19-9 levels are aimed.Materials and Methods: Gastric cancer patients (n=35), colorectal cancer patients (n=35) and healthy subjects (n=40) without any known systemic disease were included in the study. None of the participants had previously known kidney disease, serum creatinine level out of reference interval or eGFR<60 mL/min. Serum CEA and CA 19-9 levels were analysed using chemiluminescence immunoassay on Beckman Coulter UniCel® DxI 800 Immunoassay System and cystatin C was analysed with particle-enhanced turbidimetric immunoassay on Roche Diagnostics Cobas® Modular P® analyzer.Results: Cystatin C levels were significantly higher in patients’ sera (p<0.001) while there was no significant difference between groups for serum creatinine (p=0.571). Multivariate logistic regression analysis revealed that creatinine level and participation in the patient groups were the determinants of the elevated serum cystatin C concentration, respectively. Each 0.1 mg/dL elevation in creatinine level increased the possibility of having high cystatin C level 2.531 times (95% CI: 1.562-4.100). Besides the possibility of finding high cystatin C levels were 20.384 times more in the patient group (95% CI:2.992-142.196). No significant relation between CEA, CA 19-9 and cystatin C was observed when participation in patient groups, age, sex and creatinine concentration were taken into consideration (p>0.05).Conclusion: Serum cystatin C concentrations of gastric and colorectal cancer patients may be affected due to the presence of cancer besides kidney function.

Özet

Amaç: Böbrek fonksiyonun bir belirteci olarak bilinen sistatin C’nin tümör gelişiminde inhibör etki gösterdiği düşünülmektedir. Çalışmada bilinen böbrek hastalığı olmayan mide ve kolorektal kanserli olgularla sağlıklı bireylerin serum sistatin C düzeyleri arasındaki olası farkın, serum karsinoembriyonik antijen (CEA) ve karbohidrat antijen 19-9 (CA19-9) düzeyleri arasındaki ilişkinin incelenmesi amaçlanmıştır.Materyal ve metod: Çalışmaya serum kreatinin konsantrasyonu referans aralığı içerisinde yer alan ve tahmini glomerüler filtrasyon hızı (eGFH) >60 mL/dk olan mide (n=35) ve kolorektal kanserli (n=35) hastalar ile bilinen herhangi bir sistemik hastalığı olmayan sağlıklı bireyler (n=40) dahil edilmiştir. CEA ve CA 19-9 testleri kemilüminesans temelli immün yöntemle (Beckman Coulter UniCel® DxI 800 Immunoassay System) Sistatin C analizi ise partikül yüzeyi genişletilmiş immünotürbidimetrik yöntem (Roche Diagnostics Cobas® Modular P®) kullanılarak yapılmıştır.Bulgular: Mide, KRK (kolorektal kanser) ve kontrol grupları arasında serum kreatinin konsantrasyonu açısından önemli fark izlenmezken (p=0,571) sistatin C düzeyi hasta gruplarında kontrol grubuna göre anlamlı olarak daha yüksek izlenmiştir (p<0,001). Çoklu değişkenli lojistik regresyon analizinde sistatin C düzeyinin yüksek olması üzerinde sırasıyla; kreatinin düzeyi ve kanser hastası olmanın etkili olduğu bulunmuştur. Kreatinindeki her 0,1 mg/dL’lik artış sistatin C düzeyinin yüksek olma ihtimalini 2,531 kat (%95 güven aralığı: 1,562-4,100) arttırmaktadır (p<0,001). Ayrıca kontrol grubuna göre kanserli grupta sistatin C’nin yüksek olma ihtimalinin 20,384 kat (%95 güven aralığı: 2,992-142,196) fazla olduğu bulunmuştur (p=0,002). Hasta grubunda yer almak, yaş, cinsiyet ve kreatinin konsantrasyonu gibi faktörlerin etkileri göz önünde bulundurulduğunda CEA ve CA 19-9 yüksekliği ile serum sistatin C düzeyi arasında anlamlı ilişki izlenmemiştir (p>0,05). Sonuç: Mide veya kolorektal kanserli olgularda serum sistatin C düzeyinin böbrek fonksiyonunun yanısıra kanser varlığından da etkilenebileceği gözlenmiştir.Anahtar Kelimeler: Sistatin C, Katepsin, Mide Kanseri, Kolorektal Kanser

🔖

Cite This Article

AKBULUT, E. D., ERDOĞAN, S., AKBULUT, S., YILMAZ, F. M. (2020). Evaluation of Serum Cystatin C Levels And Its Relation with CEA, CA 19-9 in Patients with Gastric and Colorectal Cancer. Harran Üniversitesi Tıp Fakültesi Dergisi, Cilt: 17 - Sayı: 3, 372–377. https://ajindex.com/articles/82149

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cancer Fact Sheet [Internet]. World Health Organization. 2018 [cited 31.01.2020]. Available from:
  2. Talieri M, Papadopoulou S, Scorilas A, Xynopoulos D, Arnogianaki N, Plataniotis G, et al. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer letters. 2004;205(1):97-106
  3. Chen S, Dong H, Yang S, Guo H. Cathepsins in digestive cancers. Oncotarget. 2017;8(25):41690
  4. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2012;1824(1):68-88
  5. George JA, Gounden V. Novel glomerular filtration markers. Advances in clinical chemistry. 88: Elsevier; 2019. p. 91-119
  6. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. The journal of medical investigation. 2005;52(1, 2):1-9
  7. Kos J, Nielsen H-J, Krasovec M, Christensen IJ, Cimerman N, Stephens R, et al. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clinical cancer research. 1998;4(6):1511-6
  8. Zeng Q, Zhao Y, Yang Y, Chen XX, Wang G, Zhang P, et al. Expression of Cystatin C in human stomach neoplasms. Molecular medicine reports. 2010;3(4):607-11
  9. Saleh Y, Sebzda T, Warwas M, Kopec W, Ziólkowska J, Siewinski M. Expression of cystatin C in clinical human colorectal cancer tissues. Journal of experimental therapeutics & oncology. 2005;5(1)
  10. Bierie B, Moses HL. TGFβ: the molecular Jekyll and Hyde of cancer. Nature Reviews Cancer. 2006;6(7):506-20
  11. Sokol JP, Schiemann WP. Cystatin C Antagonizes Transforming Growth Factor β Signaling in Normal and Cancer Cells11Start-up fund from the National Jewish Medical and Research Center and by a grant from the Elsa U. Pardee Foundation to W. Schiemann. Molecular cancer research. 2004;2(3):183-95
  12. Kos J, S̆tabuc B, Cimerman N, Brünner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clinical chemistry. 1998;44(12):2556-7
  13. Nakai K, Kikuchi M, Fujimoto K, Kaneko Y, Omori S, Nakai K, et al. Serum levels of cystatin C in patients with malignancy. Clinical and experimental nephrology. 2008;12(2):132-9
  14. Zhai H, Huang J, Yang C, Fu Y, Yang B. Serum CEA and CA19-9 Levels are Associated with the Presence and Severity of Colorectal